^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Lucentis (ranibizumab)

    i
    Other names: RG-3645, RG 3645, rhuFabV2, RG3645
    Associations

    News

    Trials
    Company:
    China Medical System, Novartis, Roche, Santen
    Drug class:
    VEGF-A inhibitor
    Related drugs:
    Associations

    News

    Trials
    2d
    Lucentis Plus Tagolimumab in PD-L1+, HR+/HER2- Advanced Breast Cancer After CDK4/6 Inhibitors (clinicaltrials.gov)
    P2, N=35, Not yet recruiting, Sun Yat-sen University
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    Lucentis (ranibizumab) • Simponi (golimumab)
    9d
    M-VIVA: Identification of Molecular Signals in Vitreous Humor Associated With Suboptimal Response to Vascular Endothelial Growth Factor (VEGF) Inhibition in Neovascular Age-related Macular Degeneration (nAMD) Within a Clinical Trial Setting (clinicaltrials.gov)
    P=N/A, N=117, Recruiting, Singapore National Eye Centre
    New trial
    |
    CXCL8 (Chemokine (C-X-C motif) ligand 8)
    |
    Lucentis (ranibizumab)
    10d
    PAVILION: A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm (clinicaltrials.gov)
    P3, N=174, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Jun 2025 --> Jan 2026
    Trial completion date
    |
    Lucentis (ranibizumab)
    15d
    Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) (clinicaltrials.gov)
    P3, N=561, Recruiting, AbbVie | Not yet recruiting --> Recruiting
    Enrollment open • Adverse events • Real-world evidence
    |
    Lucentis (ranibizumab)
    16d
    Effect of Levosulpiride on Retinal Alterations in Patients With Diabetic Retinopathy and Diabetic Macular Edema (clinicaltrials.gov)
    P2, N=120, Recruiting, Carmen Clapp | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    PRL (Prolactin)
    |
    Lucentis (ranibizumab)
    20d
    AAVIATE: RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD) (clinicaltrials.gov)
    P2, N=140, Recruiting, AbbVie | Trial completion date: Aug 2026 --> Feb 2027 | Trial primary completion date: Oct 2025 --> Aug 2026
    Trial completion date • Trial primary completion date
    |
    Lucentis (ranibizumab)
    29d
    Sightspire: A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD (clinicaltrials.gov)
    P3, N=250, Recruiting, Hoffmann-La Roche | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Lucentis (ranibizumab)
    1m
    The efficacy and safety of immediate intravitreal injection of ranibizumab after vitrectomy in patients with proliferative diabetic retinopathy (ChiCTR2500107615)
    P4, N=166, Not yet recruiting, Tongji Hospital, Tongji Medical College ,Huazhong University of Science and Technology; Tongji Hospital, Tongji Medical College ,Huazhong University o
    New P4 trial
    |
    Lucentis (ranibizumab)
    2ms
    Case Report: Papillophlebitis associated with MOG-IgG-associated optic neuritis. (PubMed, Front Med (Lausanne))
    To the best of our knowledge, this is the first reported case of papillophlebitis occurring as a secondary complication of MOG-associated optic neuritis. This finding provides new insight into the spectrum of MOGAD and underscores the importance of regular fundus examinations during treatment to facilitate the timely management of ocular complications.
    Journal
    |
    MTHFR (Methylenetetrahydrofolate Reductase)
    |
    Lucentis (ranibizumab)
    2ms
    Pagoda: A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME (clinicaltrials.gov)
    P3, N=634, Recruiting, Hoffmann-La Roche | Trial completion date: Nov 2026 --> Nov 2027 | Trial primary completion date: Nov 2026 --> Nov 2027
    Trial completion date • Trial primary completion date
    |
    Lucentis (ranibizumab)
    4ms
    ATMOSPHERE: Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD (clinicaltrials.gov)
    P2/3, N=630, Recruiting, AbbVie | Trial completion date: May 2026 --> Nov 2027 | Trial primary completion date: May 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Lucentis (ranibizumab)
    4ms
    Stereotactic Radiotherapy for Wet AMD (STAR) (clinicaltrials.gov)
    P3, N=411, Completed, King's College Hospital NHS Trust | Active, not recruiting --> Completed
    Trial completion
    |
    Lucentis (ranibizumab)